Comparative effectiveness of a glucagon-like peptide-1 receptor agonist versus a dipeptidyl peptide-4 inhibitor on kidney and cardiovascular outcomes in routine clinical practice

Whether glucagon-like peptide-1 receptor agonists (GLP1-RA) reduce detrimental kidney outcomes is uncertain. In secondary analyses, trials have shown consistent reductions in macroalbuminuria, but inconclusive results about kidney function decline. To help clarify this, we conducted a cohort study to compare kidney and cardiovascular outcomes in individuals who started GLP1-RA or dipeptidyl peptidase-4 inhibitors (DPP4i) (reduces degradation of endogenous GLP1). The primary outcome was a composite of sustained doubling of creatinine, kidney failure or kidney death.

Source: Kidney International - November 23, 2021 Category: Urology & Nephrology Authors: Yang Xu, Edouard L. Fu, Catherine M. Clase, Faizan Mazhar, Meg J. Jardine, Juan-Jesus Carrero Tags: clinical investigation Source Type: research